menu

Allergy & respiratory

Transforming allergy and respiratory drug development through disruptive innovation

Accelerate the development of allergy and respiratory therapies by tapping into the latest equipment, methodologies and technical, scientific, and therapeutic expertise.

Female doctor examining patient

Quintiles helped develop or commercialize 95% of the Top 20 best-selling allergy products of 2014

Overcoming the unique hurdles of allergy and respiratory drug development takes the right expertise on your side.

Despite major medical advances in the fields of allergy and respiratory medicine, there is still no definitive cure for chronic conditions such as asthma, COPD, IPF, and CF. And with research in these indications being one of the most intensely competitive areas in drug development, sponsors have only increasing pressures to deliver more effective treatments through their clinical development programs.

From changing regulatory requirements to identifying the best methodologies for sample collection and biomarker analysis, our respiratory experts can help your team navigate the complexities of this challenging environment.

Quintiles brings together a global team of pulmonologists and respiratory medical advisors, with senior project directors and clinical staff trained and/or certified on guidelines including GINA, GOLD and ERS/ATS. The result? From expertise across clinical trial design and biomarker deployment, to deep knowledge of regulatory, market access and commercial pathways, Quintiles can help you strategically optimize your path to market. Combining this knowledge with data-driven insights can help reduce study cycle times, optimize costs and improve the odds of market success.

Experience you can trust

Transforming respiratory developmentView our infographic to learn more about our proven success, experience and innovation, and how together we can work together to improve your probability of success.
  • Quintiles helped develop or commercialize 95% of the Top 20 best-selling allergy products of 2014
  • Quintiles helped develop or commercialize 90% of the Top 20 best-selling respiratory products of 2014
  • Quintiles has provided clinical services for >170 respiratory studies involving >84,000 subjects and >16,500 investigator sites in 66 countries since 2009

The ART Center of Excellence

Quintiles Allergy and Respiratory (ART) Center of Excellence can help advance your studies in these and related indications from early clinical development to post-marketing studies. With pulmonologists, respiratory medical and senior advisors, and experienced operational staff across the globe, we can help:

Leadership in advancing allergy and respiratory clinical research

  • Integrate the scientific, therapeutic, operational, and commercial components of your programs for improved outcomes
  • Select and find the right patient populations for your studies utilizing precision medicine
  • Reduce study cycle times
  • Improve your overall trial productivity and efficiency
  • Improve your probability for regulatory and market success
Supporting these efforts is Quintiles BioSpit initiative--created to improve the quality of allergy and respiratory research by harmonizing methods and sputum data analysis across collaborating centers. Spanning early clinical development to global lab testing, the BioSpit Initiative ensures delivery of high quality sputum induction and processing methods and ongoing support throughout the study.



Ready to advance your respiratory and allergy studies globally?

  • Dedicated Center for Respiratory & Biomarker Research
  • Proven access to COPD, Asthma, and IPF patient networks
  • Inhaled challenge models including allergy, LPS, and exercise
  • Global Centralized sputum and airway sample laboratory
  • Integrated tissue handling and biomarker identification
  • Targeted global site selection for allergy immunotherapeutic studies
  • Expertise in drug delivery for PK/PD bioequivalence device studies
Leverage the collective expertise of our multi-disciplinary team   +

Integrate the scientific, therapeutic, operational, and commercial components of your programs for improved outcomes.

Quintiles brings together a global team of pulmonologists and respiratory medical advisors, with senior project directors and clinical staff trained and/or certified on guidelines including Global Initiative for Asthma (GINA), Global Initiative for Chronic Obstructive Lung Disease (GOLD), and European Respiratory Society (ERS) and American Thoracic Society (ATS) spirometry guidelines.  Read some our latest thinking on key indications

COPD A global survey conducted to determine frequency of exacerbations in COPD patients (poster)
Asthma A global survey conducted to determine current management of asthma (poster)
IPF Key Considerations for Conducting Clinical Trials in Idiopathic Pulmonary Fibrosis (article)
CF Conducting Cystic Fibrosis Clinical Trials: Methodological, Practical, and Ethical Considerations (poster and article)

Quintiles study and team experience also includes:

Access global scale to access the right sites and patients   +

By leveraging our network of established and experienced sites, Quintiles can provide targeted global site selection for allergy, immunotherapeutic and respiratory studies with access to chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), and alpha1-antitrypsin deficiency (A1AD).
  • Global reach spans northern and southern hemispheres for sustained recruitment momentum from proof of concept (PoC) into later phase studies
  • Global landscape surveys for indications including asthma, COPD, CF, A1AD covering diagnosis, treatment, standard of care, prevalence of disease
  • Allergy chamber available for environmental allergy studies
Incorporate translational medicine and biomarker integration strategies   +

Identifying robust biomarkers which can serve as a surrogate endpoints that are acceptable to regulators can be challenging.
Quintiles biomarker services, supported by laboratory services through Q2 Solutions, can help you to select and find the right patient populations for your studies by integrating biomarkers into your selection criteria during Phase I and into later phase studies.

  • Expertise in drug delivery for PK/PD bioequivalence, and generic/biosimilar studies 
  • Acute knowledge of first-in-man (FIM) and first-in-patient (FIP) studies
  • Collaborative links to King’s College, Imperial College and University College London
  • Global centralized sputum and airway sample laboratory at Quintiles Phase I unit in London (QLON) (read our latest blog)
  • Challenge studies, bronchoscopy studies, cardiopulmonary exercise test (CPET)
  • Vast experience in spirometry, imaging, data capture methods
Tailored solutions to meet your budget and timeline   +

Setting the course for clinical program success takes up-front planning—learn more about our suite of services designed to help our customers map the best path forward.
Allergy and Respiratory Services   +

Ready to advance your respiratory and allergy studies globally?
  • Dedicated Center for Respiratory & Biomarker Research
  • Proven access to COPD, Asthma, and IPF patient networks
  • Inhaled challenge models including allergy, LPS, and exercise
  • Global Centralized sputum and airway sample laboratory
  • Integrated tissue handling and biomarker identification
  • Targeted global site selection for allergy immunotherapeutic studies
  • Expertise in drug delivery for PK/PD bioequivalence device studies

The power of possibilities

Deploy disruptive innovation to transform allergy and respiratory drug development.

Video Spotlights
Getting more value from Respiratory Clinical Trials
Getting more value from Respiratory Clinical Trials